Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Shares Outstanding (2016 - 2025)

CytomX Therapeutics' Shares Outstanding history spans 12 years, with the latest figure at $170.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 112.47% year-over-year to $170.2 million; the TTM value through Dec 2025 reached $170.2 million, up 112.47%, while the annual FY2025 figure was $170.2 million, 112.47% up from the prior year.
  • Shares Outstanding reached $170.2 million in Q4 2025 per CTMX's latest filing, up from $165.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $170.2 million in Q4 2025 to a low of $65.0 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $83.8 million, with a median of $66.8 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: grew 0.61% in 2022, then surged 112.47% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $65.4 million in 2021, then increased by 1.28% to $66.2 million in 2022, then grew by 1.63% to $67.3 million in 2023, then grew by 19.0% to $80.1 million in 2024, then soared by 112.47% to $170.2 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Shares Outstanding are $170.2 million (Q4 2025), $165.1 million (Q3 2025), and $164.9 million (Q2 2025).